Children's Medical Center Corporation

Beth Israel Deaconess Medical Center, Inc.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Harvard College

Howard Hughes Medical Institute

Bing Chen

Stephen C Harrison

Michael Scott Seaman

Dan H Barouch

Joseph P Nkolola

Gary H Frey

Tianshu Xiao

Gary T Frey

Jia Chen

Joseph P Nkoloa

Dan C Barouch

Jun Zhang

Yongfei Cai

Joseph P Nikolola

Described herein are compounds that inhibits the membrane proximal external region (MPER) of a viral envelope (Env), as well as and compositions thereof. Further provided herein are methods for treating or preventing a viral infection comprises administering to a subject in need thereof an agent or compound that inhibits the MPER of a viral Env. In certain embodiments, the viral infection is an HIV infection.

Compositions and methods for targeting a viral infection

Provided herein, in some aspects, are polypeptide monomers comprising an angiotensin-converting enzyme 2 (ACE2) ectodomain and an oligomerization domain. Also provided herein are oligomeric complexes comprising ACE2 monomers. Methods of using such to monomers and oligomeric complexes for the diagnosis, prevention, and treatment of viral infections such as the coronavirus are also provided.

High-affinity human ACE2 construct for use in diagnosing and treating coronaviruses

Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.

Biochemically stabilized HIV-1 Env trimer vaccine

Isolated, antigenic polypeptides including a pre-hairpin intermediate conformation of gp41 and vectors encoding such polypeptides are provided. Exemplary pre-hairpin intermediate conformations of gp41 include an oligomerization domain; a heptad repeat 2 motif; and a membrane-proximal external region, where the polypeptide lacks a heptad repeat 1 motif, and where the isolated, antigenic polypeptides elicit production of a broadly neutralizing antibody against HIV when injected into a subject. Antibodies that bind to a pre-hairpin intermediate conformation of gp41 and methods of making antibodies a that bind to pre-hairpin intermediate conformation of gp41 are also provided. Vaccines against a pre-hairpin intermediate conformation of gp41, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. Methods of screening compounds that bind to an isolated, pre-hairpin intermediate conformation of gp41 are further provided.

Antigenic polypeptides comprising pre-hairpin intermediate conformations of HIV-1 GP41

Biochemically stabilized HIV-1 env trimer vaccine

Biochemically stabilized HIV-1 ENV trimer vaccine

Isolated, antigenic polypeptides including a prehairpin intermediate conformation of gp41 and vectors encoding such polypeptides are provided. Antibodies that bind to a prehairpin intermediate conformation of gp41 and methods of making antibodies a that bind to prehairpin intermediate conformation of gp41 are also provided. Vaccines against a prehairpin intermediate conformation of gp41, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. Methods of screening compounds that bind to an isolated, prehairpin intermediate conformation of gp41 are further provided.

Fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies

Growing community of inventors

Chestnut Hill, MA, United States of America

Bing Chen